299 related articles for article (PubMed ID: 32870433)
21. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.
Gold HK; Torres FW; Garabedian HD; Werner W; Jang IK; Khan A; Hagstrom JN; Yasuda T; Leinbach RC; Newell JB
J Am Coll Cardiol; 1993 Apr; 21(5):1039-47. PubMed ID: 8459055
[TBL] [Abstract][Full Text] [Related]
22. Pharmacology of argatroban.
Jeske WP; Fareed J; Hoppensteadt DA; Lewis B; Walenga JM
Expert Rev Hematol; 2010 Oct; 3(5):527-39. PubMed ID: 21083469
[TBL] [Abstract][Full Text] [Related]
23. No effect of clot age or thrombolysis on argatroban's inhibition of thrombin.
Hantgan RR; Jerome WG; Hursting MJ
Blood; 1998 Sep; 92(6):2064-74. PubMed ID: 9731064
[TBL] [Abstract][Full Text] [Related]
24. The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro.
Raaz U; Kaeberich A; Maegdefessel L; Buerke M; Busshardt M; Schubert S; Russ M; Plehn A; Ebelt H; Werdan K; Schlitt A
Thromb Haemost; 2010 Apr; 103(4):808-14. PubMed ID: 20174756
[TBL] [Abstract][Full Text] [Related]
25. Cooperative antithrombotic effect from the simultaneous inhibition of thrombin and factor Xa.
Giardino EC; Haertlein BJ; de Garavilla L; Costanzo MJ; Damiano BP; Andrade-Gordon P; Maryanoff BE
Blood Coagul Fibrinolysis; 2010 Mar; 21(2):128-34. PubMed ID: 20010091
[TBL] [Abstract][Full Text] [Related]
26. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia.
Lewis BE; Wallis DE; Hursting MJ; Levine RL; Leya F
Chest; 2006 Jun; 129(6):1407-16. PubMed ID: 16778256
[TBL] [Abstract][Full Text] [Related]
27. Argatroban Attenuates Diabetic Cardiomyopathy in Rats by Reducing Fibrosis, Inflammation, Apoptosis, and Protease-Activated Receptor Expression.
Bulani Y; Sharma SS
Cardiovasc Drugs Ther; 2017 Jun; 31(3):255-267. PubMed ID: 28695302
[TBL] [Abstract][Full Text] [Related]
28. Argatroban: a direct thrombin inhibitor for heparin-induced thrombocytopenia and other clinical applications.
Chen JL
Heart Dis; 2001; 3(3):189-98. PubMed ID: 11975790
[TBL] [Abstract][Full Text] [Related]
29. Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study.
Fisser C; Winkler M; Malfertheiner MV; Philipp A; Foltan M; Lunz D; Zeman F; Maier LS; Lubnow M; Müller T
Crit Care; 2021 Apr; 25(1):160. PubMed ID: 33910609
[TBL] [Abstract][Full Text] [Related]
30. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin.
Berry CN; Girardot C; Lecoffre C; Lunven C
Thromb Haemost; 1994 Sep; 72(3):381-6. PubMed ID: 7855788
[TBL] [Abstract][Full Text] [Related]
31. In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban.
He S; Wallèn H; Bark N; Blombäck M
J Thromb Thrombolysis; 2013 Feb; 35(2):131-9. PubMed ID: 22843196
[TBL] [Abstract][Full Text] [Related]
32. Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.
Hursting MJ; Soffer J
Drug Saf; 2009; 32(3):203-18. PubMed ID: 19338378
[TBL] [Abstract][Full Text] [Related]
33. Argatroban and inhibition of the vasomotor actions of thrombin.
Winn MJ; Jain K; Ku DD
J Cardiovasc Pharmacol; 1993 Nov; 22(5):754-60. PubMed ID: 7506329
[TBL] [Abstract][Full Text] [Related]
34. [Argatroban: pharmacological properties and anaesthesiological aspects].
Kleinschmidt S; Stephan B; Pindur G; Bauer C
Anaesthesist; 2006 Apr; 55(4):443-50. PubMed ID: 16389543
[TBL] [Abstract][Full Text] [Related]
35. Argatroban.
McKeage K; Plosker GL
Drugs; 2001; 61(4):515-22; discussion 523-4. PubMed ID: 11324681
[TBL] [Abstract][Full Text] [Related]
36. Argatroban inhibits staphylothrombin.
Hijikata-Okunomiya A; Kataoka N
J Thromb Haemost; 2003 Sep; 1(9):2060-1. PubMed ID: 12941055
[No Abstract] [Full Text] [Related]
37. Influence of argatroban on coagulation parameters in heparin-induced thrombocytopenia patients after cardiothoracic surgery.
Harder S; Merz M; Klinkhardt U; Lorenz H; Koster A
J Thromb Haemost; 2007 Sep; 5(9):1982-4. PubMed ID: 17723141
[No Abstract] [Full Text] [Related]
38. Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome.
Cruz-González I; López-Jiménez R; Perez-Rivera A; Yan BP
Expert Opin Drug Metab Toxicol; 2012 Nov; 8(11):1483-93. PubMed ID: 22970706
[TBL] [Abstract][Full Text] [Related]
39. Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia.
Kondo LM; Wittkowsky AK; Wiggins BS
Ann Pharmacother; 2001 Apr; 35(4):440-51. PubMed ID: 11302409
[TBL] [Abstract][Full Text] [Related]
40. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
